Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2013 Earnings Results

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 2.43%

Arrowhead Pharmaceuticals reported a loss of $0.41 per share, which did not meet expectations, leading to a stock decline of 2.43%. The lack of revenue data and forward guidance contributed to investor uncertainty. Management's cautious tone suggests they are focused on long-term projects rather than immediate financial performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.41	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding future performance. They emphasized the importance of their ongoing projects but did not provide specific financial guidance.

Management did not provide specific guidance for future performance.

The company is focusing on ongoing research and development efforts.

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 2.43%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 2.43%

Key numbers

Management commentary